InMode (NASDAQ:INMD), a global aesthetic device manufacturer, has officially unveiled its upgraded product Morpheus8 Cool, built on the new expandable Morpheus8MAX platform. The release brings comprehensive improvements in safety, patient comfort and operational standardization to the well‑established Morpheus8 radio‑frequency microneedling system, further strengthening its benchmark position in fractional radio‑frequency (FRF) microneedling.
Since its initial launch, Morpheus8 has become one of the world’s most widely‑used RF microneedling devices, with over 3 million clinical procedures performed globally. Combining insulated microneedles, bipolar radio‑frequency and multi‑layer Burst Pulse technology, it addresses fine lines, enlarged pores, acne scars, skin laxity and cellulite across face, neck and body areas. It is also the first fractional RF microneedling device cleared by the FDA for soft‑tissue contraction. Traditional models feature adjustable‑depth gold‑plated insulated microneedles that deliver RF energy precisely into the epidermis, dermis and subcutaneous fat layers to trigger collagen and elastin regeneration. The body handpiece reaches a maximum treatment depth of 8 mm, supporting both delicate facial rejuvenation and body contour tightening.
The biggest innovation of the new Morpheus8 Cool is its Cool Comfort surface‑cooling technology. The redesigned cooled applicator intelligently regulates epidermal temperature while RF thermal energy is delivered, significantly reducing intra‑procedure heat and stinging to improve patient experience. Two operating modes are available: Guided Mode, with pre‑loaded clinically‑validated standard parameters for consistent, reproducible treatment outcomes; and Manual Mode, offering full customisation for experienced practitioners to tailor protocols to individual skin conditions and concerns.
Dr. Michael Kreindel, Co‑Founder and CTO of InMode, commented that Morpheus8 Cool was developed based on real‑world feedback from tens of thousands of clinicians worldwide. While retaining the core Burst multi‑pulse technology, the upgrade lowers operational barriers and balances efficacy, safety and comfort for both novice and expert practitioners.
Industry insight: RF microneedling continues to gain market traction, yet clinical safety remains a key focus for the aesthetic sector. Industry experts remind readers that Morpheus8 is a medical‑grade device rather than a non‑salon beauty tool. Adverse events including burns, scarring and local fat atrophy are mostly caused by excessive parameter settings or improper technique instead of device defects. Treatments must be performed by qualified dermatologists or plastic surgeons; operation by unlicensed beauty‑salon staff is strictly prohibited.
Indications include facial fine lines, enlarged pores, atrophic acne scars, uneven pigmentation, jawline laxity; as well as body laxity, stretch marks and cellulite on flanks, thighs and abdomen. The standard protocol recommends 1‑3 sessions at 3‑4‑week intervals. Mild post‑treatment redness normally resolves within 2‑5 days. Collagen remodelling continues over time, with optimal results typically visible 1‑3 months post‑procedure. Annual maintenance sessions are advised to sustain outcomes.
For aesthetic clinics, the Morpheus8 product line remains a high‑revenue treatment, with single‑session pricing ranging from USD 800 to 2500. Thanks to the modular Morpheus8MAX platform, clinics can add further handpieces later without full‑unit replacement, lowering hardware upgrade costs and accelerating market adoption of RF microneedling within minimally‑invasive anti‑aging.
Industry analysts note the aesthetic market is shifting from the pursuit of “deeper energy output” toward a balanced focus on efficacy, safety and patient comfort. The Morpheus8 Cool iteration reflects this trend: built‑in standardised presets plus epidermal thermal protection help minimise operator‑driven risks while meeting growing consumer demand for less painful, shorter‑downturn aesthetic treatments.
